Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready
Rq Biotechnology Limited has 2 pending office actions in Biotechnology & Pharmaceuticals. Those matters involve 2 distinct examiners and 2 distinct art units, so the pending work is distributed across separate examination assignments.
CORNELIUS, CLAIRE ADRIENNE is the busiest examiner, with 1 pending action. The portfolio therefore does not place all pending matters with that examiner, making matter-specific prosecution review appropriate.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 2 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| CORNELIUS, CLAIRE ADRIENNE | 1 | 71.4% | +0.0% |
| SIFFORD, JEFFREY MARK | 1 | 55.1% | +32.8% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18264241 | ANTIBODIES | CORNELIUS, CLAIRE ADRIENNE | — |
| 18264226 | ANTIBODIES | SIFFORD, JEFFREY MARK | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18264226 | ANTIBODIES | SIFFORD, JEFFREY MARK | — |
| Art Unit | Apps |
|---|---|
| 1672 | 1 |
| 1671 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18264241 | ANTIBODIES | CORNELIUS, CLAIRE ADRIENNE | 1672 | §101§112 | Non-Final OA | — | Pending | Aug 03, 2023 |
| 18264226 | ANTIBODIES | SIFFORD, JEFFREY MARK | 1671 | §101§102§112 | Non-Final OA | — | Pending | Aug 03, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialRq Biotechnology Limited has 2 pending office actions as of October 2026, spread across 2 art units and 2 examiners.
Claire Adrienne Cornelius has the most, with 1 of Rq Biotechnology Limited's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
